menu
    • menu
    [{"orgOrder":0,"company":"United Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JORDAN","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Fiber","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"United Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"United Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"United Pharmaceuticals","sponsor":"Delta Consultants","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JORDAN","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"New Infant Formula","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"United Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Pharmaceuticals \/ Delta Consultants","highestDevelopmentStatusID":"1","companyTruncated":"United Pharmaceuticals \/ Delta Consultants"},{"orgOrder":0,"company":"United Pharmaceuticals","sponsor":"Axiodis CRO","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JORDAN","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"New Infant Formula","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"United Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Pharmaceuticals \/ Axiodis CRO","highestDevelopmentStatusID":"1","companyTruncated":"United Pharmaceuticals \/ Axiodis CRO"},{"orgOrder":0,"company":"United Pharmaceuticals","sponsor":"Slb Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JORDAN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"United Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Pharmaceuticals \/ Slb Pharma","highestDevelopmentStatusID":"1","companyTruncated":"United Pharmaceuticals \/ Slb Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by United Pharmaceuticals

    Menu

    United Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            United Pharmaceuticals

                            Jordan arrow
                            Pharma MES 2025
                            Not Confirmed

                            United Pharmaceuticals

                            Jordan arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : New Infant Formula

                            Therapeutic Area : Gastroenterology

                            Study Phase : Undisclosed

                            Sponsor : Axiodis CRO

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evolution of Functional Gastrointestinal Disorders in Infants Fed With a New Infant Formula

                            Details : New Infant Formula is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Gastrointestinal Diseases.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            July 05, 2024

                            Lead Product(s) : New Infant Formula

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Undisclosed

                            Sponsor : Axiodis CRO

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            United Pharmaceuticals

                            Jordan arrow
                            Pharma MES 2025
                            Not Confirmed

                            United Pharmaceuticals

                            Jordan arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Sponsor : Slb Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of Tolerance, Efficacy and Safety of an Hydrolyzed Formula in Infants With IgE/Non-IgE Mediated CMA...

                            Details : This drug candidate is currently being evaluated in clinical studies for the treatment of Milk Hypersensitivity.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 01, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Sponsor : Slb Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            United Pharmaceuticals

                            Jordan arrow
                            Pharma MES 2025
                            Not Confirmed

                            United Pharmaceuticals

                            Jordan arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : New Infant Formula

                            Therapeutic Area : Gastroenterology

                            Study Phase : Undisclosed

                            Sponsor : Delta Consultants

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of the Efficacy of a New Specific Infant Formula in Case of Functional Constipation

                            Details : New Infant Formula is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Constipation.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            April 22, 2022

                            Lead Product(s) : New Infant Formula

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Undisclosed

                            Sponsor : Delta Consultants

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            United Pharmaceuticals

                            Jordan arrow
                            Pharma MES 2025
                            Not Confirmed

                            United Pharmaceuticals

                            Jordan arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fiber

                            Therapeutic Area : Dermatology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of an Adapted Formula on Atopic Dermatitis.

                            Details : Fiber is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Dermatitis, Atopic.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            April 08, 2022

                            Lead Product(s) : Fiber

                            Therapeutic Area : Dermatology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth